![]() ![]() Roche, which is headquartered in Basel, Switzerland, will add Philadelphia to its list of worldwide product development sites. “Since founding Spark eight years ago, Philadelphia has been part of our company’s DNA and we’re proud to continue to call Philadelphia home for many years to come.”Īs part of Spark’s now projected 1 million-square-foot campus in Philadelphia, the anticipated 500,000-square-foot, multi-story building will bring hundreds of the greatest minds in gene therapy together under one roof to drive science forward, challenge the inevitability of genetic disease, and serve as a Roche global center of excellence for gene therapy manufacturing. “Through this significant investment and plans to more than double our physical footprint, we're poised for continued growth as we seek to develop the next generation of genetic medicines as a member of the Roche Group,” said Jeff Marrazzo, chief executive officer and co-founder, of Spark Therapeutics. Terms of the ground lease, including financial terms, were not disclosed. Through a 99-year ground lease of Drexel’s F Lot, the new center will be located at the intersection of 30th and Chestnut Streets and will create opportunities for collaboration with Drexel and Philadelphia’s booming life sciences community. Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced plans to invest an initial $575 million in the creation of a new, state-of-the-art gene therapy innovation center on Drexel University’s campus in the heart of Philadelphia’s University City neighborhood. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |